Table 3.
Long term trial for ziprasidone.
| Authors | Zipr. dose (mg/day) | Comparator | n | Duration | Efficacy of ziprasidone |
|---|---|---|---|---|---|
| Hirsch et al34 | 80 | Haloperidol (5 mg) | 301 | 28 w. | Equivalent efficacy |
| Harvey et al35 | 102 | Haloperidol (11,5 mg) | 186 | 196 w. | Higher efficacy |
| Arato et al27 | 40–80–160 | Placebo | 278 | 48 w. | Low probability of relapse than placebo |
| Breier et al28 | 80–160 | Olanzapine (10–20 mg) | 548 | 28 w. | Less effective than olanzapine |
| Simpson et al39 | 80–120–160 | Olanzapine (5–10–15 mg) | 269 | 24 w. | Comparable long term efficacy |
| Liebermann et al30 | 40–160 | Olanz 7,5–30 Queti 200–800 Risp 1,5–6 |
1493 | 72 w. | Time of discontinuation longer in the olanzapine group |
| Stroup et al31 | 40–160 | Olanz 7,5–30 Queti 200–800 Risp 1,5–6 |
444 | 24 w. | Risp et olanz were more effective than quet and ziprasidone |
| Addington et al29 | 80 to 160 | Risperidone (6 to 10 mg) | 139 | 44 w. | Similar efficacy |
| Potkin36 Stahl et al1 |
80–120 | Haloperidol (5–20 mg) | 599 | 196 w. | Improvement in remission, negative symptoms and quality of life |